Uno studio che utilizza un nuovo farmaco, Nivolumab, in combinazione con farmaci chemioterapici per trattare un tipo di cancro chiamato carcinoma rinofaringeo (NPC)
Uno studio di fase 2 che utilizza la chemioimmunoterapia con gemcitabina, cisplatino e nivolumab nel carcinoma rinofaringeo (NPC) di nuova diagnosi
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Altro: Quality-of-Life Assessment
- Droga: Cisplatin
- Procedura: Biospecimen Collection
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Altro: Questionnaire Administration
- Procedura: Echocardiography Test
- Procedura: Multigated Acquisition Scan
- Procedura: Positron Emission Tomography
- Biologico: Nivolumab
- Droga: Gemcitabine
- Procedura: Biopsy Procedure
- Procedura: Chest Radiography
- Altro: Electronic Health Record Review
- Radiazione: Radiation Therapy
- Altro: Fluciclovine F18
- Procedura: X-Ray Imaging
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor and blood) for future research studies.
X. To compare dental x-rays in patients prior to radiation and 1 year post radiation to evaluate for dental caries and bone health.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy and blood sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australia, 2310
- Reclutamento
- John Hunter Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: (02) 4985 5180
-
Investigatore principale:
- Kristy McCarthy
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Reclutamento
- Alberta Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 403-220-6898
- Email: research4kids@ucalgary.ca
-
Investigatore principale:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Reclutamento
- University of Alberta Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 780-407-8798
- Email: pedsoncologyresearch@ahs.ca
-
Investigatore principale:
- Sarah J. McKillop
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Reclutamento
- Hospital for Sick Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 416-813-7654
- Email: ask.CRS@sickkids.ca
-
Investigatore principale:
- Avram E. Denburg
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Reclutamento
- The Montreal Children's Hospital of the MUHC
-
Contatto:
- Site Public Contact
- Numero di telefono: 514-412-4445
- Email: info@thechildren.com
-
Investigatore principale:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Reclutamento
- Centre Hospitalier Universitaire Sainte-Justine
-
Investigatore principale:
- Monia Marzouki
-
Contatto:
- Site Public Contact
- Numero di telefono: 514-345-4931
- Email: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Reclutamento
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contatto:
- Site Public Contact
- Numero di telefono: 819-820-6480
- Email: crcinformation.chus@ssss.gouv.qc.ca
-
Investigatore principale:
- Stephanie Vairy
-
-
-
-
-
Christchurch, Nuova Zelanda, 8011
- Reclutamento
- Christchurch Hospital
-
Investigatore principale:
- Tristan Pettit
-
Contatto:
- Site Public Contact
- Numero di telefono: 03 364 0640
-
-
Auckland
-
Grafton, Auckland, Nuova Zelanda, 1145
- Reclutamento
- Starship Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 0800 728 436
-
Investigatore principale:
- Leander D. Timothy
-
-
-
-
-
San Juan, Porto Rico, 00926
- Reclutamento
- University Pediatric Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 787-474-0333
-
Investigatore principale:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- Children's Hospital of Alabama
-
Contatto:
- Site Public Contact
- Numero di telefono: 205-638-9285
- Email: oncologyresearch@peds.uab.edu
-
Investigatore principale:
- Jamie M. Aye
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85016
- Reclutamento
- Phoenix Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 602-546-0920
-
Investigatore principale:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202-3591
- Reclutamento
- Arkansas Children's Hospital
-
Investigatore principale:
- Michael W. Bishop
-
Contatto:
- Site Public Contact
- Numero di telefono: 501-364-7373
-
-
California
-
Downey, California, Stati Uniti, 90242
- Reclutamento
- Kaiser Permanente Downey Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 626-564-3455
-
Investigatore principale:
- Robert M. Cooper
-
Loma Linda, California, Stati Uniti, 92354
- Reclutamento
- Loma Linda University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 909-558-4050
-
Investigatore principale:
- Albert Kheradpour
-
Los Angeles, California, Stati Uniti, 90027
- Reclutamento
- Children's Hospital Los Angeles
-
Investigatore principale:
- Rachana Shah
-
Contatto:
- Site Public Contact
- Numero di telefono: 323-361-4110
-
Madera, California, Stati Uniti, 93636
- Reclutamento
- Valley Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 559-353-3000
- Email: Research@valleychildrens.org
-
Investigatore principale:
- Ruetima Titapiwatanakun
-
Oakland, California, Stati Uniti, 94611
- Reclutamento
- Kaiser Permanente-Oakland
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Aarati V. Rao
-
Oakland, California, Stati Uniti, 94609
- Reclutamento
- UCSF Benioff Children's Hospital Oakland
-
Investigatore principale:
- Jennifer G. Michlitsch
-
Contatto:
- Site Public Contact
- Numero di telefono: 510-428-3264
- Email: PedOncRschOAK@ucsf.edu
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- Rady Children's Hospital - San Diego
-
Contatto:
- Site Public Contact
- Numero di telefono: 858-966-5934
-
Investigatore principale:
- William D. Roberts
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- UCSF Medical Center-Mission Bay
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-3222
- Email: cancertrials@ucsf.edu
-
Investigatore principale:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- Children's Hospital Colorado
-
Investigatore principale:
- Navin R. Pinto
-
Contatto:
- Site Public Contact
- Numero di telefono: 303-764-5056
- Email: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Reclutamento
- Connecticut Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 860-545-9981
-
Investigatore principale:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Reclutamento
- Alfred I duPont Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- Children's National Medical Center
-
Investigatore principale:
- Jeffrey S. Dome
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-476-2800
- Email: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- Reclutamento
- UF Health Cancer Institute - Gainesville
-
Contatto:
- Site Public Contact
- Numero di telefono: 352-273-8010
- Email: cancer-center@ufl.edu
-
Investigatore principale:
- Brian Stover
-
Jacksonville, Florida, Stati Uniti, 32207
- Reclutamento
- Nemours Children's Clinic-Jacksonville
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Sridhi Patel
-
Miami, Florida, Stati Uniti, 33155
- Reclutamento
- Nicklaus Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-624-2778
-
Investigatore principale:
- Ziad A. Khatib
-
Orlando, Florida, Stati Uniti, 32806
- Reclutamento
- Arnold Palmer Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 321-841-5357
- Email: Jennifer.spinelli@orlandohealth.com
-
Investigatore principale:
- Zhongbo Hu
-
Orlando, Florida, Stati Uniti, 32827
- Reclutamento
- Nemours Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Sridhi Patel
-
Pensacola, Florida, Stati Uniti, 32504
- Reclutamento
- Nemours Children's Clinic - Pensacola
-
Contatto:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Investigatore principale:
- Jeffrey H. Schwartz
-
Tampa, Florida, Stati Uniti, 33607
- Reclutamento
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 813-357-0849
- Email: jennifer.manns@baycare.org
-
Investigatore principale:
- Don E. Eslin
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Reclutamento
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Investigatore principale:
- Sarah G. Mitchell
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-785-0232
- Email: Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Lurie Children's Hospital-Chicago
-
Investigatore principale:
- Amy L. Walz
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-880-4562
-
Chicago, Illinois, Stati Uniti, 60637
- Sospeso
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Riley Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-248-1199
-
Investigatore principale:
- Marissa Just
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Non ancora reclutamento
- University of Kentucky/Markey Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 859-257-3379
-
Investigatore principale:
- James T. Badgett
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70118
- Reclutamento
- Children's Hospital New Orleans
-
Investigatore principale:
- Maria C. Velez-Yanguas
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-894-5377
-
-
Maine
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- Maine Children's Cancer Program
-
Investigatore principale:
- Aaron R. Weiss
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Investigatore principale:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute
-
Investigatore principale:
- Allison F. O'Neill
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-442-3324
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Reclutamento
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic in Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- Reclutamento
- University of Mississippi Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 601-815-6700
-
Investigatore principale:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- Children's Mercy Hospitals and Clinics
-
Investigatore principale:
- Keith J. August
-
Contatto:
- Site Public Contact
- Numero di telefono: 816-302-6808
- Email: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Frederick S. Huang
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Reclutamento
- Children's Hospital and Medical Center of Omaha
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-955-3949
-
Investigatore principale:
- Jill C. Beck
-
Omaha, Nebraska, Stati Uniti, 68198
- Reclutamento
- University of Nebraska Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Investigatore principale:
- Jill C. Beck
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- Hackensack University Medical Center
-
Investigatore principale:
- Katharine Offer
-
Contatto:
- Site Public Contact
- Numero di telefono: 551-996-2897
-
Neptune City, New Jersey, Stati Uniti, 07753
- Reclutamento
- Jersey Shore Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-776-4240
-
Investigatore principale:
- Katharine Offer
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Investigatore principale:
- Scott Moerdler
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-8675
-
Newark, New Jersey, Stati Uniti, 07112
- Reclutamento
- Newark Beth Israel Medical Center
-
Investigatore principale:
- Scott Moerdler
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-926-7230
- Email: Christine.Kosmides@rwjbh.org
-
Investigatore principale:
- Teena Bhatla
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Albany Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 518-262-5513
-
Investigatore principale:
- Lauren R. Weintraub
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center - Moses Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-379-6866
- Email: eskwak@montefiore.org
-
Investigatore principale:
- Alice Lee
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28203
- Reclutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-9376
-
Investigatore principale:
- Joel A. Kaplan
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Investigatore principale:
- Jessica M. Sun
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-275-3853
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- East Carolina University
-
Contatto:
- Site Public Contact
- Numero di telefono: 252-744-1015
- Email: eubankss@ecu.edu
-
Investigatore principale:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Wake Forest University Health Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 336-713-6771
-
Investigatore principale:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Investigatore principale:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Reclutamento
- Cincinnati Children's Hospital Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 513-636-2799
- Email: cancer@cchmc.org
-
Investigatore principale:
- Brian K. Turpin
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Rainbow Babies and Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 216-844-5437
-
Investigatore principale:
- Duncan S. Stearns
-
Columbus, Ohio, Stati Uniti, 43205
- Reclutamento
- Nationwide Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 614-722-6039
- Email: Melinda.Triplet@nationwidechildrens.org
-
Investigatore principale:
- Mark A. Ranalli
-
Dayton, Ohio, Stati Uniti, 45404
- Reclutamento
- Dayton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-4055
-
Investigatore principale:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-402-9543
- Email: Morgan_M.Horton@lvhn.org
-
Investigatore principale:
- Jacob A. Troutman
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Reclutamento
- Penn State Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 717-531-6012
-
Investigatore principale:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia
-
Contatto:
- Site Public Contact
- Numero di telefono: 267-425-5544
- Email: CancerTrials@email.chop.edu
-
Investigatore principale:
- Theodore W. Laetsch
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- Children's Hospital of Pittsburgh of UPMC
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-692-8570
- Email: jean.tersak@chp.edu
-
Investigatore principale:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti, 29203
- Reclutamento
- Prisma Health Richland Hospital
-
Investigatore principale:
- Stuart L. Cramer
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- BI-LO Charities Children's Cancer Center
-
Investigatore principale:
- Aniket Saha
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
Investigatore principale:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38105
- Reclutamento
- Saint Jude Children's Research Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-226-4343
- Email: referralinfo@stjude.org
-
Investigatore principale:
- Catherine G. Lam
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University/Ingram Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-811-8480
-
Investigatore principale:
- Scott C. Borinstein
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- The Children's Hospital at TriStar Centennial
-
Contatto:
- Site Public Contact
- Numero di telefono: 615-342-1919
-
Investigatore principale:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Stati Uniti, 78723
- Reclutamento
- Dell Children's Medical Center of Central Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 512-628-1902
- Email: TXAUS-DL-SFCHemonc.research@ascension.org
-
Investigatore principale:
- Shannon M. Cohn
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Investigatore principale:
- Avanthi T. Shah
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Cook Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 682-885-2103
- Email: CookChildrensResearch@cookchildrens.org
-
Investigatore principale:
- Chelsee Greer
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 713-798-1354
- Email: burton@bcm.edu
-
Investigatore principale:
- Mehmet F. Okcu
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- UT MD Anderson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Najat C. Daw
-
San Antonio, Texas, Stati Uniti, 78207
- Reclutamento
- Children's Hospital of San Antonio
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-704-2894
- Email: bridget.medina@christushealth.org
-
Investigatore principale:
- Julie Voeller
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- Reclutamento
- University of Virginia Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 434-243-6303
- Email: uvacancertrials@hscmail.mcc.virginia.edu
-
Investigatore principale:
- Brian C. Belyea
-
Norfolk, Virginia, Stati Uniti, 23507
- Reclutamento
- Children's Hospital of The King's Daughters
-
Contatto:
- Site Public Contact
- Numero di telefono: 757-668-7243
- Email: CCBDCresearch@chkd.org
-
Investigatore principale:
- Melissa S. Mark
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- VCU Massey Comprehensive Cancer Center
-
Investigatore principale:
- Madhu S. Gowda
-
Contatto:
- Site Public Contact
- Numero di telefono: 804-628-6430
- Email: CTOclinops@vcu.edu
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-987-2000
-
Investigatore principale:
- Sarah E. Leary
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Mary Bridge Children's Hospital and Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 253-403-1461
- Email: research@multicare.org
-
Investigatore principale:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Children's Hospital of Wisconsin
-
Investigatore principale:
- Angela Steineck
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-955-4727
- Email: MACCCTO@mcw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) (8th edition) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
- to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female)
- to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) â ¥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
Altri nomi:
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo ECHO
Altri nomi:
Undergo MUGA
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo tissue biopsy
Altri nomi:
Undergo chest x-ray
Altri nomi:
Ancillary studies Receive radiation therapy
Altri nomi:
Given IV
Altri nomi:
Undergo dental x-ray
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
Lasso di tempo: Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events (8th edition). IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Event-free survival (EFS)
Lasso di tempo: From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
Lasso di tempo: At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
Lasso di tempo: At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
Lasso di tempo: Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
EFS
Lasso di tempo: At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
Lasso di tempo: From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
Lasso di tempo: At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
Lasso di tempo: Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
Lasso di tempo: Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
Lasso di tempo: Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
Lasso di tempo: At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
Lasso di tempo: At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
Lasso di tempo: At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
|
Dental changes
Lasso di tempo: At baseline (prior to radiation) and up to 1 post radiation
|
Will include dental caries and osteoradionecrosis. Dental caries will be quantified as the number of teeth with caries, and bone health will be evaluated as a categorical variable using 0 for no disease and a score of 1-4 to match stage of periodontal disease as described in 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions was co-presented by the American Academy of Periodontology and the European Federation of Periodontology staging framework. Changes over time will be evaluated using paired analyses. Given the small sample size, results will primarily be descriptive, with patient's dental caries and bone health data summarized using descriptive statistics. |
At baseline (prior to radiation) and up to 1 post radiation
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Robyn D Gartrell, Children's Oncology Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie stomatognatiche
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Malattie otorinolaringoiatriche
- Neoplasie faringee
- Neoplasie otorinolaringoiatriche
- Malattie nasofaringee
- Malattie faringee
- Neoplasie nasofaringee
- Carcinoma rinofaringeo
- Aminoacidi, peptidi e proteine
- Proteine
- Composti eterociclici, 1-anello
- Composti eterociclici
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Tecniche citologiche
- Citodiagnosi
- Fenomeni fisici
- Attrezzatura e forniture
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Elementi
- Metalli
- Tecniche diagnostiche, chirurgiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Metalli, pesante
- Composti di platino
- Fenomeni elettromagnetici
- Fenomeni magnetici
- Elementi di transizione
- Radiazioni elettromagnetiche
- Radiazione, ionizzante
- Nivolumab
- Gemcitabina
- Cisplatino
- 1,2-diamminocicloesaneplatino II citrato
- Radioterapia
- Radiazione
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Platino
- Raggi X.
- Phantoms, imaging
- Fluciclovino F-18
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2023-07208
- U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2023-07208 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- ARAR2221 (Altro identificatore: CTEP)
- ARAR2221 (Altro identificatore: Children's Oncology Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .